Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q3 2025 Earnings Presentation

11 slides from Abcellera Biologics's earnings presentation, Nov 6, 2025

  1. Slide 1: Q3 2025 Business Update

    Q3 2025 BUSINESS UPDATE COPYRIGHT © ABCELLERA November 6, 2025

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation contains forward-looking statements, including statements made These statements involve risks, uncertainties and other factors that may cause pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act actual results, levels of activity, perfor

  3. Slide 3: 2025 Priorities: Q3 2025 Update

    2025 PRIORITIES: Q3 2025 UPDATE Clinical trials on track, completed platform investments, and started activities at clinical manufacturing site. Q3 2025 Business Update Completed platform ABCL635 Phase 1 clinical investments by the first Nominated trials initiated (June 2025) an additional half of th

  4. Slide 4: Appointed AbCellera's First Chief Medical Officer

    TEAM Appointed AbCellera’s First Chief Medical Officer Dr. Sarah Noonberg MD, PhD Q3 2025 Business Update Dr. Noonberg is leveraging her clinical development background to advance AbCellera’s pipeline of antibody-based therapeutics: COPYRIGHT © ABCELLERA 4

  5. Slide 5: Financials Update

    5 COPYRIGHT © ABCELLERA Q3 2025 Business Update FINANCIALS UPDATE Q3 2025

  6. Slide 6: We Have the Capabilities and the Capital to Execute on Our Strategy

    ~$680M in available liquidity We have the to execute on our strategy* capabilities and Q3 2025 Business Update the capital to ~$520M in total cash, cash equivalents, & marketable securities* execute on our strategy. ~$160M in total available government funding* COPYRIGHT © ABCELLERA * As of Septembe

  7. Slide 7: Continuing Portfolio Growth With First AbCellera-Led Programs in the Clinic

    Continuing portfolio growth with first AbCellera-led programs in the clinic. Cumulative # of Cumulative # of PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC WITH DOWNSTREAMS Q3 2025 Business Update Partner-led AbCellera-led COPYRIGHT © ABCELLERA Note: Showing year-end figures except for most-

  8. Slide 8: Operating Expenses Reflect R&D Investments

    Operating expenses reflect R&D investments. Revenue USD Operating Expenses USD LICENSING RESEARCH & SALES & GENERAL & RESEARCH FEES DEVELOPMENT MARKETING ADMIN Q3 2025 Business Update +$14.1M $55.0M $41.0M +$2.9M $22.1M $19.1M $9.0M -$0.2M $6.5M $0.1M COPYRIGHT © ABCELLERA $8.8M $3.1M $2.9M $6.3M Q3

  9. Slide 9: Net Loss of $57M; Equivalent to ($0.19) per Share

    Net loss of $57M; equivalent to ($0.19) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q3 2025 Business Update ($51.1M) ($57.1M) Q3 2024 Q3 2025 Q3 2024 Q3 2025 COPYRIGHT © ABCELLERA 9

  10. Slide 10: Approximately $520M in Total Cash, Equivalents, and Marketable Securities

    Approximately $520M in total cash, equivalents, and marketable securities. Cash Flows USD Q3 2025 Business Update $469M Marketable Securities $413M Marketable Securities $156M $62M Marketable Cash & Securities (net) Equivalents $83M Cash & Equivalents COPYRIGHT © ABCELLERA * Restricted cash (includi

  11. Slide 11: Thank You

    11 COPYRIGHT © ABCELLERA Q3 2025 Business Update THANK YOU

AbCellera Biologics — Q3 2025 Earnings Presentation on 6ix